Rosatom Scientists Patent Tech for Separating Radium, Actinium, Thorium
ECONOMY & POLICY

Rosatom Scientists Patent Tech for Separating Radium, Actinium, Thorium

The technology developed by nuclear scientists has enabled the production of actinium-225 that has a wide application in atomedics. Specialists from the Department of Radionuclide Sources and Preparations at the Research Institute of Nuclear Reactors, State Scientific Centre (RIAR JSC belongs to Rosatom’s Scientific division) have obtained a patent for the technology of producing an actinium-225-based radioactive preparation.

Due to its unique properties, the isotope is deemed promising for use in the nuclear medicine and cancer therapy. The production technology ensures the product's high quality, as evidenced during all mandatory stages of monitoring of its specifications. Nowadays, alpha emitters, such as atinium-225, are regarded as one of the most promising areas in the atomedics. These isotopes are often referred to as "the future of cancer treatment". Rosatom and healthcare facilities are actively working in this field.

"Obtaining a patent is a significant milestone for the institute, one of the four global producers of actinium-225. This new development allowed the company, which ranks among the top three at Rosatom, to strengthen its position as an innovation leader. It is also significantly contributing to the advancements in the domestic science," said Andrey Shikunov, Deputy Director for Development and International Business at RIAR JSC.

The technology was developed by Dimitrovgrad scientists under an agreement with the Ministry of Industry and Trade of the Russian Federation. The Ministry granted the company a subsidy for scientific research and development following the competitive selection process.

The technology developed by nuclear scientists has enabled the production of actinium-225 that has a wide application in atomedics. Specialists from the Department of Radionuclide Sources and Preparations at the Research Institute of Nuclear Reactors, State Scientific Centre (RIAR JSC belongs to Rosatom’s Scientific division) have obtained a patent for the technology of producing an actinium-225-based radioactive preparation. Due to its unique properties, the isotope is deemed promising for use in the nuclear medicine and cancer therapy. The production technology ensures the product's high quality, as evidenced during all mandatory stages of monitoring of its specifications. Nowadays, alpha emitters, such as atinium-225, are regarded as one of the most promising areas in the atomedics. These isotopes are often referred to as the future of cancer treatment. Rosatom and healthcare facilities are actively working in this field. Obtaining a patent is a significant milestone for the institute, one of the four global producers of actinium-225. This new development allowed the company, which ranks among the top three at Rosatom, to strengthen its position as an innovation leader. It is also significantly contributing to the advancements in the domestic science, said Andrey Shikunov, Deputy Director for Development and International Business at RIAR JSC. The technology was developed by Dimitrovgrad scientists under an agreement with the Ministry of Industry and Trade of the Russian Federation. The Ministry granted the company a subsidy for scientific research and development following the competitive selection process.

Next Story
Infrastructure Transport

Lack of Bidders Stalls VOC Port’s Rs 70.56 Bn Harbour Project Again

The VOC Port Authority’s Rs 70.56 billion outer harbour project has once again faced a setback, with the latest tender process cancelled due to the absence of qualified bidders. This marks the second failed attempt to secure participation for the mega infrastructure initiative.The tender has reportedly been withdrawn from the active list of bids, and the authority is now expected to re-evaluate and possibly restructure the project to enhance its appeal to potential developers.The port authority had initially floated the Request for Proposal (RFP) in December 2024, following the cancellation ..

Next Story
Infrastructure Transport

Sea Lord Containers Opens Cryogenic LPG Terminal in Mangalore

Sea Lord Containers (SCL), a wholly-owned subsidiary of Aegis Logistics, has commissioned a new cryogenic Liquified Petroleum Gas (LPG) terminal in Mangalore. The facility, which became operational on 12 June 2025, offers a static storage capacity of 82,000 metric tons (MT), significantly strengthening the region’s LPG logistics infrastructure.The terminal was developed by SCL on behalf of Aegis Vopak Terminals, an associate company of Aegis Logistics. The asset is expected to be transferred to Aegis Vopak Terminals Limited at a later date, with formal updates to be shared separately with st..

Next Story
Infrastructure Urban

Cochin Port and Oil India Partner for Offshore Exploration Support

The Cochin Port Authority (CoPA) has signed a Memorandum of Understanding (MoU) with Oil India (OIL) to establish a shore base facility supporting offshore oil exploration in the Kerala-Konkan Basin. The agreement was formalised at a ceremony held at CoPA, Willingdon Island, on 12 June 2025, in the presence of senior officials from both organisations.Under the partnership, Cochin Port will provide critical logistics infrastructure for OIL’s offshore drilling operations, expected to begin later in 2025. The planned shore base will include a dedicated warehouse, dry bulk handling plant, and an..

Advertisement

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Advertisement

Talk to us?